CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Agios Pharmaceuticals Inc   (NASDAQ: AGIO)

Agios Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Agios Pharmaceuticals Inc in the second quarter 2026?
Agios Pharmaceuticals Inc recorded a cumulative net loss of $-411 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -35.67%.

Within the Major Pharmaceutical Preparations industry 131 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1866 to 3061.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change -25.08 % -24.37 % -22.57 % -21.05 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -411 -423 -413 -401 650
Return On Equity (TTM) -35.67 % -34.11 % -31.07 % -28.35 % 43.31 %
AGIO's Total Ranking # 3061 # 1866 # 2147 # 2728 # 170
Equity (TTM) in Millions 1,026 1,109 1,193 1,284 1,370
Seq. Equity Change -7.49 % -7.04 % -7.1 % -6.22 % -6.61 %
Seq. Net Income Change - - - - -

Back to AGIO Management Effectiveness >> AGIO's 5 Years Annual ROE >> Compare AGIO ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 132
Sector # 340
Overall # 3061

Return On Equity Statistics
High Average Low
247.29 %
-11.3 %
-76.67 %
(Dec 31 2013)   (Dec 31 2017)



  News about Agios Pharmaceuticals Inc Return on Equity ROE

“Agios Pharmaceuticals Sees Strong Q4 Performance and Advances Mitapivat to Transform Thalassemia Treatment”,

Agios Pharmaceuticals Reports Q4 and Full Year 2024 Financial Results, Advances Mitapivat for Thalassemia TreatmentAgios Pharmaceuticals Inc. a biopharmaceutical company focused on discovering and developing innovative therapies for rare diseases, has announced its financial results for the fourth quarter and full year of 2024. The report highlights significant advancements in the company s lead product, Mitapivat (commercially known as PYRUKYND), as Agios seeks to obtain regulatory approval for its use in treating adult patients diagnosed with both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. Financial Performance OverviewIn a year marked by significant developments and challenges, Agios reported a noteworthy return on equity (ROE) of 58.94% in the fourth quarter of 2024, showcasing a remarkable improvement compared to the previous year. This performance stands in stark contrast to Agios average ROE of -23.27%, and marks a significant rebound within the sector, where only one other firm had a higher return on equity within the Major Pharmaceutical Preparations industry. Nonetheless, it is important to note that while Agios ROE increased considerably, it fell somewhat relative to previous periods primarily due to a decline in net income. Despite these fluctuations, the overall ranking of Agios in terms of ROE improved from 94th position in the third quarter of 2024 to 50th position in the latest quarter, indicating a positive trajectory in operational performance.



AGIO Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 1,193 1,541 811 1,101 1,292
Y / Y Equity Change -22.57 % 90 % -26.33 % -14.8 % 223.4 %
Net Income in Millions -413 674 -352 -232 1,605
Y / Y Net Income Change - - - - -
Return On Equity -34.6 % 43.72 % -43.41 % -21.06 % 124.21 %

Back to AGIO Management Effectiveness >> AGIO's 5 Years Annual ROE >> Compare AGIO ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
AGIO's' Return on Equity at Yahoo Finance
AGIO's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for AGIO's Competitors
Subscribers only: Roe for Agios Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for AGIO's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-13T23:38:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.